Use of a Novel Artificial Intelligence Assisted Platform to Assess Optimal Dosing and Treatment Strategy of Erythropoiesis-stimulating Agents (ESA) in Hemodialysis Patients

NCT05032651 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

130

Enrollment

OTHER

Sponsor class

Conditions

End Stage Renal Disease on Dialysis

Interventions

DEVICE: novel artificial intelligence assisted platform

Sponsor

Kaohsiung Medical University Chung-Ho Memorial Hospital

Collaborators

[object Object]